Meta-analysis of the difference of peripheral inflammatory factors in Alzheimer’s disease and vascular dementia_Chinese Journal of Evidence-Based Medicine

Authors：

LI Zongyang , NI Jingnian , WEI Mingqing , LI Ting , SHI Jing ,  TIAN Jinzhou

Dong Zhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, P.R.China;

Corresponding?author：

TIAN Jinzhou, Email: jztian@hotmail.com

Keywords：

Alzheimer’s disease; Vascular dementia; Inflammatory factor; Difference; Systematic review

DOI：

10.7507/1672-2531.202010132

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the data of peripheral inflammatory markers in patients with Alzheimer’s disease (AD) and vascular dementia (VaD) to further indicate pathogenesis and antidiastole.Methods PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP databases were electronically searched to collect studies on peripheral inflammatory markers in patients with AD and VaD from inception to July 2020. Two reviewers independently screened literature, extracted data, and assessed risk of bias of included studies, and meta-analysis was performed by using Stata 15.1SE software.Results A total of 30 studies involving 2 377 patients were included. The results of meta-analysis showed that the IL-6 level was higher in VaD group than that in AD group (SMD=?0.477, 95%CI ?0.944 to ?0.009, P=0.046). However, there were no statistical difference in peripheral IL-1β (SMD=?0.034, 95%CI ?0.325 to 0.257, P=0.818), TNF-α (SMD=0.409, 95%CI ?0.152 to 0.970, P=0.153) or CRP (SMD=0.277, 95%CI ?0.228 to 0.782, P=0.282) levels.Conclusions These findings suggest that IL-6 may be sensitive markers to distinguish AD from VaD. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the conclusions.

Citation： LI Zongyang, NI Jingnian, WEI Mingqing, LI Ting, SHI Jing, TIAN Jinzhou. Meta-analysis of the difference of peripheral inflammatory factors in Alzheimer’s disease and vascular dementia. Chinese Journal of Evidence-Based Medicine, 2021, 21(5): 578-585. doi: 10.7507/1672-2531.202010132 Copy

1.	Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal, 2012, 2012: 756357.
2.	Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm, 2006, 74: 505-530.
3.	Tarkowski E, Liljeroth AM, Minthon L, et al. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull, 2003, 61(3): 255-260.
4.	Wada-Isoe K, Wakutani Y, Urakami K, et al. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol Scand, 2004, 110(2): 124-127.
5.	Yasutake C, Kuroda K, Yanagawa T, et al. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci, 2006, 256(7): 402-406.
6.	Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res, 2007, 41(8): 686-693.
7.	Uslu S, Akarkarasu ZE, Ozbabalik D, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia. Neurochem Res, 2012, 37(7): 1554-1559.
8.	De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev, 2001, 122(16): 1985-1995.
9.	丁彬彬, 鄔建民, 介勇, 等. 阿爾茨海默病和血管性癡呆患者血清炎癥因子和生化指標的檢測及臨床意義. 檢驗醫學, 2016, 31(5): 363-367.
10.	丁彬彬, 鄧飛飛, 徐堅, 等. 阿爾茨海默病患者血清炎性因子與血凝指標的變化. 疑難病雜志, 2017, 16(1): 32-35.
11.	于愷, 張強, 韓杰. 阿爾茨海默病患者血清和腦脊液中腫瘤壞死因子 α 及白細胞介素 8 的水平. 中國臨床康復, 2005, 9(45): 21-23.
12.	亢濤. 阿爾茨海默病和血管性癡呆患者血清炎癥因子和生化指標的檢測及臨床意義. 檢驗醫學與臨床, 2019, 16(20): 2966-2968.
13.	侯燕, 陳民, 王金俠. 老年期癡呆患者的血脂, C 反應蛋白水平及認知功能. 中國老年學雜志, 2016, 36(11): 2643-2644.
14.	倪紅芬, 胡瑾瑾, 沈曄. 老年癡呆患者血清同型半胱氨酸、C 反應蛋白、葉酸、維生素 B12 檢測分析. 中國高等醫學教育, 2016, (5): 133, 137.
15.	劉俊恒, 陳正林. 阿爾茨海默病及血管性癡呆患者血清膽固醇、IL-6和VitB12等水平的臨床觀測. 江蘇大學學報(醫學版), 2006, 16(1): 48-49, 52.
16.	劉俊恒, 潘繼承, 朱建一, 等. 阿爾茨海默病及血管性癡呆患者血脂、CRP、高半胱氨酸等指標的比較. 臨床檢驗雜志, 2006, 24(4): 311-312.
17.	劉玲, 羅高權, 劉琦. 老年癡呆患者代謝指標及炎癥因子的水平及意義. 中國老年學雜志, 2016, 36(23): 5858-5860.
18.	原鐵錚. 阿爾茨海默病與血管性癡呆患者血脂及 CRP 水平變化. 中國老年學雜志, 2011, 31(8): 1439-1440.
19.	吳佳慧. 老年性癡呆與血管性癡呆臨床量表評分、中醫證候及血清學指標比較分析. 北京: 北京中醫藥大學, 2018.
20.	周田田. 在阿爾茨海默癥與血管性癡呆患者的血清細胞炎性因子及血脂比較研究. 中國民康醫學, 2015, (11): 4-5.
21.	張蘭. 同型半胱氨酸和 C 反應蛋白對阿爾茨海默病與血管性癡呆的鑒別診斷價值. 中國實用醫藥, 2016, 11(11): 113-114.
22.	彭艷, 常運奇, 肖飛. 血漿 C 反應蛋白在三種重度癡呆患者中的比較. 飲食保健, 2018, 5(36): 13-14.
23.	方麗麗. 超敏 C 反應蛋白和同型半胱氨酸在鑒別阿爾茨海默病及血管性癡呆中的對比分析. 齊齊哈爾醫學院學報, 2016, 37(14): 1831-1832.
24.	方芳, 蔣安杰, 晏勇, 等. 炎癥因子及脂質代謝在阿爾茨海默病和血管性癡呆中的臨床意義. 中國老年學雜志, 2010, 30(24): 3632-3633.
25.	朱詠新, 周維智, 劉曉紅, 等. 癡呆患者血漿凝血及炎性因子變化的相關性研究. 腦與神經疾病雜志, 2008, 16(5): 622-626.
26.	李龍宣, 趙斌, 許志恩, 等. 癡呆患者血清和腦脊液中炎前和抗炎細胞因子的變化. 第四軍醫大學學報, 2007, 28(5): 453-455.
27.	楊春華, 徐雯霞, 龐小芬. 老年癡呆患者代謝指標及炎癥因子的臨床分析. 中華老年多器官疾病雜志, 2015, (8): 616-619.
28.	王靜, 杜紅興. 血管性癡呆和阿爾茨海默病血清炎癥因子、臨床生化指標的變化. 中國醫學創新, 2020, 17(9): 40-44.
29.	胡軍, 原琳琳, 胡長春, 等. 早期阿爾茨海默病血清 CRP IL-6TG 及血漿 HDL-C 診斷分析. 中國實用神經疾病雜志, 2017, 20(15): 9-11.
30.	蔡志友, 晏勇, 晏寧, 等. 阿爾茨海默病患者血清中血管內皮生長因子和炎癥因子相關性研究. 中國老年學雜志, 2008, 28(10): 998-999.
31.	鄔烈銘, 朱文芳, 裴瑜, 等. 老年性癡呆患者認知功能與血清炎性細胞因子濃度的相關研究. 中華臨床醫師雜志(電子版), 2012, 6(11): 2970-2973.
32.	陳賤蘭, 陳前萍, 曾順生. 老年癡呆患者血清同型半胱氨酸、C 反應蛋白、葉酸、維生素 B12 檢測研究. 當代醫學, 2017, 23(28): 39-41.
33.	靳秀, 王圣海, 馬曉佳, 等. 癡呆患者認知功能障礙與血清 IL-1β、IL-6、TNF-α、Hcy、hs-CRP 和 IL-1RA 水平的相關性. 精神醫學雜志, 2019, 32(2): 111-114.
34.	韓杰, 王琳, 張昱, 等. 阿爾茨海默病患者血清和腦脊液中白細胞介素-6 及白細胞介素-6 受體水平的研究. 中國臨床神經科學, 2002, 10(1): 64-66.
35.	黃燕. 老年不同類型癡呆與血漿 C-反應蛋白、同型半胱氨酸的相關性分析. 兵團醫學, 2014, 42(4): 7-8.
36.	Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry, 2017, 88(10): 876-882.
37.	Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91(9): e867-e877.
38.	Miwa K, Okazaki S, Sakaguchi M, et al. Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia. Eur J Neurol, 2016, 23(3): 656-663.
39.	Sudduth TL, Weekman EM, Price BR, et al. Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID). Neuroscience, 2017, 341: 42-51.
40.	Pan W, Zhu W, Gao Q, et al. Effect of Yin-Xing-Tong-Zhi tablets on improving vascular cognitive impairment no dementia. Evid Based Complement Alternat Med, 2018, 2018: 6184260.
41.	Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J, 2014, 35(9): 578-589.
42.	Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G> C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol, 2002, 22(12): 2066-2071.
43.	Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med, 1999, 106(5): 506-512.
44.	Hoshi T, Kitagawa K, Yamagami H, et al. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke, 2005, 36(4): 768-772.
45.	Waje-Andreassen U, Kr?kenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand, 2005, 111(6): 360-365.
46.	Gigante B, Strawbridge RJ, Velasquez IM, et al. Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One, 2015, 10(3): e0119980.
47.	Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc, 2017, 6(10): e005077.
48.	Zhang F, Jiang L. Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat, 2015, 11: 243-256.
49.	Dá Mesquita S, Ferreira AC, Sousa JC, et al. Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev, 2016, 68: 547-562.
50.	段新飛, 宋利宏, 董小雪, 等. 不同年齡階段血管性癡呆患者腦脊液中炎癥因子檢測及其臨床意義. 標記免疫分析與臨床, 2020, 27(7): 1208-1212.
51.	Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci, 2008, 118(12): 1659-1672.
52.	Baranowska-Bik A, Bik W, Wolinska-Witort E, et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett, 2008, 29(1): 75-79.
53.	Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol, 2008, 193(1-2): 183-187.
54.	Chou RC, Kane M, Ghimire S, et al. Treatment for rheumatoid arthritis and risk of alzheimer's disease: a nested case-control analysis. CNS Drugs, 2016, 30(11): 1111-1120.
55.	Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother, 2017, 17(1): 17-32.
56.	Schweingruber N, Reichardt SD, Lühder F, et al. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol, 2012, 24(1): 174-182.

1. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal, 2012, 2012: 756357.
2. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm, 2006, 74: 505-530.
3. Tarkowski E, Liljeroth AM, Minthon L, et al. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull, 2003, 61(3): 255-260.
4. Wada-Isoe K, Wakutani Y, Urakami K, et al. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol Scand, 2004, 110(2): 124-127.
5. Yasutake C, Kuroda K, Yanagawa T, et al. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci, 2006, 256(7): 402-406.
6. Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res, 2007, 41(8): 686-693.
7. Uslu S, Akarkarasu ZE, Ozbabalik D, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia. Neurochem Res, 2012, 37(7): 1554-1559.
8. De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev, 2001, 122(16): 1985-1995.
9. 丁彬彬, 鄔建民, 介勇, 等. 阿爾茨海默病和血管性癡呆患者血清炎癥因子和生化指標的檢測及臨床意義. 檢驗醫學, 2016, 31(5): 363-367.
10. 丁彬彬, 鄧飛飛, 徐堅, 等. 阿爾茨海默病患者血清炎性因子與血凝指標的變化. 疑難病雜志, 2017, 16(1): 32-35.
11. 于愷, 張強, 韓杰. 阿爾茨海默病患者血清和腦脊液中腫瘤壞死因子 α 及白細胞介素 8 的水平. 中國臨床康復, 2005, 9(45): 21-23.
12. 亢濤. 阿爾茨海默病和血管性癡呆患者血清炎癥因子和生化指標的檢測及臨床意義. 檢驗醫學與臨床, 2019, 16(20): 2966-2968.
13. 侯燕, 陳民, 王金俠. 老年期癡呆患者的血脂, C 反應蛋白水平及認知功能. 中國老年學雜志, 2016, 36(11): 2643-2644.
14. 倪紅芬, 胡瑾瑾, 沈曄. 老年癡呆患者血清同型半胱氨酸、C 反應蛋白、葉酸、維生素 B12 檢測分析. 中國高等醫學教育, 2016, (5): 133, 137.
15. 劉俊恒, 陳正林. 阿爾茨海默病及血管性癡呆患者血清膽固醇、IL-6和VitB12等水平的臨床觀測. 江蘇大學學報(醫學版), 2006, 16(1): 48-49, 52.
16. 劉俊恒, 潘繼承, 朱建一, 等. 阿爾茨海默病及血管性癡呆患者血脂、CRP、高半胱氨酸等指標的比較. 臨床檢驗雜志, 2006, 24(4): 311-312.
17. 劉玲, 羅高權, 劉琦. 老年癡呆患者代謝指標及炎癥因子的水平及意義. 中國老年學雜志, 2016, 36(23): 5858-5860.
18. 原鐵錚. 阿爾茨海默病與血管性癡呆患者血脂及 CRP 水平變化. 中國老年學雜志, 2011, 31(8): 1439-1440.
19. 吳佳慧. 老年性癡呆與血管性癡呆臨床量表評分、中醫證候及血清學指標比較分析. 北京: 北京中醫藥大學, 2018.
20. 周田田. 在阿爾茨海默癥與血管性癡呆患者的血清細胞炎性因子及血脂比較研究. 中國民康醫學, 2015, (11): 4-5.
21. 張蘭. 同型半胱氨酸和 C 反應蛋白對阿爾茨海默病與血管性癡呆的鑒別診斷價值. 中國實用醫藥, 2016, 11(11): 113-114.
22. 彭艷, 常運奇, 肖飛. 血漿 C 反應蛋白在三種重度癡呆患者中的比較. 飲食保健, 2018, 5(36): 13-14.
23. 方麗麗. 超敏 C 反應蛋白和同型半胱氨酸在鑒別阿爾茨海默病及血管性癡呆中的對比分析. 齊齊哈爾醫學院學報, 2016, 37(14): 1831-1832.
24. 方芳, 蔣安杰, 晏勇, 等. 炎癥因子及脂質代謝在阿爾茨海默病和血管性癡呆中的臨床意義. 中國老年學雜志, 2010, 30(24): 3632-3633.
25. 朱詠新, 周維智, 劉曉紅, 等. 癡呆患者血漿凝血及炎性因子變化的相關性研究. 腦與神經疾病雜志, 2008, 16(5): 622-626.
26. 李龍宣, 趙斌, 許志恩, 等. 癡呆患者血清和腦脊液中炎前和抗炎細胞因子的變化. 第四軍醫大學學報, 2007, 28(5): 453-455.
27. 楊春華, 徐雯霞, 龐小芬. 老年癡呆患者代謝指標及炎癥因子的臨床分析. 中華老年多器官疾病雜志, 2015, (8): 616-619.
28. 王靜, 杜紅興. 血管性癡呆和阿爾茨海默病血清炎癥因子、臨床生化指標的變化. 中國醫學創新, 2020, 17(9): 40-44.
29. 胡軍, 原琳琳, 胡長春, 等. 早期阿爾茨海默病血清 CRP IL-6TG 及血漿 HDL-C 診斷分析. 中國實用神經疾病雜志, 2017, 20(15): 9-11.
30. 蔡志友, 晏勇, 晏寧, 等. 阿爾茨海默病患者血清中血管內皮生長因子和炎癥因子相關性研究. 中國老年學雜志, 2008, 28(10): 998-999.
31. 鄔烈銘, 朱文芳, 裴瑜, 等. 老年性癡呆患者認知功能與血清炎性細胞因子濃度的相關研究. 中華臨床醫師雜志(電子版), 2012, 6(11): 2970-2973.
32. 陳賤蘭, 陳前萍, 曾順生. 老年癡呆患者血清同型半胱氨酸、C 反應蛋白、葉酸、維生素 B12 檢測研究. 當代醫學, 2017, 23(28): 39-41.
33. 靳秀, 王圣海, 馬曉佳, 等. 癡呆患者認知功能障礙與血清 IL-1β、IL-6、TNF-α、Hcy、hs-CRP 和 IL-1RA 水平的相關性. 精神醫學雜志, 2019, 32(2): 111-114.
34. 韓杰, 王琳, 張昱, 等. 阿爾茨海默病患者血清和腦脊液中白細胞介素-6 及白細胞介素-6 受體水平的研究. 中國臨床神經科學, 2002, 10(1): 64-66.
35. 黃燕. 老年不同類型癡呆與血漿 C-反應蛋白、同型半胱氨酸的相關性分析. 兵團醫學, 2014, 42(4): 7-8.
36. Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry, 2017, 88(10): 876-882.
37. Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91(9): e867-e877.
38. Miwa K, Okazaki S, Sakaguchi M, et al. Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia. Eur J Neurol, 2016, 23(3): 656-663.
39. Sudduth TL, Weekman EM, Price BR, et al. Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID). Neuroscience, 2017, 341: 42-51.
40. Pan W, Zhu W, Gao Q, et al. Effect of Yin-Xing-Tong-Zhi tablets on improving vascular cognitive impairment no dementia. Evid Based Complement Alternat Med, 2018, 2018: 6184260.
41. Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J, 2014, 35(9): 578-589.
42. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G> C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol, 2002, 22(12): 2066-2071.
43. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med, 1999, 106(5): 506-512.
44. Hoshi T, Kitagawa K, Yamagami H, et al. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke, 2005, 36(4): 768-772.
45. Waje-Andreassen U, Kr?kenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand, 2005, 111(6): 360-365.
46. Gigante B, Strawbridge RJ, Velasquez IM, et al. Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One, 2015, 10(3): e0119980.
47. Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc, 2017, 6(10): e005077.
48. Zhang F, Jiang L. Neuroinflammation in Alzheimer's disease. Neuropsychiatr Dis Treat, 2015, 11: 243-256.
49. Dá Mesquita S, Ferreira AC, Sousa JC, et al. Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev, 2016, 68: 547-562.
50. 段新飛, 宋利宏, 董小雪, 等. 不同年齡階段血管性癡呆患者腦脊液中炎癥因子檢測及其臨床意義. 標記免疫分析與臨床, 2020, 27(7): 1208-1212.
51. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci, 2008, 118(12): 1659-1672.
52. Baranowska-Bik A, Bik W, Wolinska-Witort E, et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett, 2008, 29(1): 75-79.
53. Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol, 2008, 193(1-2): 183-187.
54. Chou RC, Kane M, Ghimire S, et al. Treatment for rheumatoid arthritis and risk of alzheimer's disease: a nested case-control analysis. CNS Drugs, 2016, 30(11): 1111-1120.
55. Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother, 2017, 17(1): 17-32.
56. Schweingruber N, Reichardt SD, Lühder F, et al. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol, 2012, 24(1): 174-182.

Chinese Journal of Evidence-Based Medicine

Meta-analysis of the difference of peripheral inflammatory factors in Alzheimer’s disease and vascular dementia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content